Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 63Neoplasms 5Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Recurrence 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Hyperglycemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

palbociclib 1exemestane 1Letrozole 1Hydroxychloroquine 1BID protein, human 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer × exemestane × 1 year × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡